Quick answer In the REDEFINE trials CagriSema is given once weekly by subcutaneous injection, with both components titrated in parallel from 0.25 mg + 0.25 mg up to a 2.4 mg + 2.4 mg weekly target
This is a typical picture for the entire class of regenerative peptides: a strong signal from preclinical models (rodents, cell cultures), without full phase III clinical confirmation
Should combined protocols continue indefinitely, or do individuals eventually transition to maintenance approaches or discontinue entirely
possible transient effects may include flushing, headache, or injection-site reactions
What is cagrilintide
The thymus shrinks due to the pressure of hormones such as androgens, estrogens, progesterones, and corticosteroids, with the majority of the shrinkage occurring in the 20s and 30s, a process known as thymic involution, 2m6s